$44 Billion by 2024. $250 Billion by 2024. Whatever. I’ve not been very impressed by the many attempts to estimate how much money biosimilars could save the US health care system. Even the more well-known estimates of biosimilar savings, like those from RAND and Express Scripts, have been little more than games of "pin the … Continue reading $7.6 Billion Estimate on Savings Lost From Approved, Nonlaunched Biosimilars Could Be Low
Tag: Biosimilar savings
Payers Focus More on a Biosimilar’s Price Than on Clinical Data: A Retrospective
It can be fun to go back in time! That’s the case with an old column I wrote for the Center for Biosimilars, just after Zarxio was approved. Here, I reprint a portion of the column, with some additional commentary. A RAND study from 2014 boldly predicted $44.2 billion in savings from biologic drugs over … Continue reading Payers Focus More on a Biosimilar’s Price Than on Clinical Data: A Retrospective
Infliximab Biosimilars Savings Could Exceed $400 Million Dollars Annually
Everyone with an opinion believes that biosimilar drug use will save the health system considerable money. Calculations for biosimilar savings have been hampered by several factors. For example, previous high estimates have not been based on real-life scenarios. Only 3 biosimilars have been launched and utilized in the US; so little experience has been gained on which … Continue reading Infliximab Biosimilars Savings Could Exceed $400 Million Dollars Annually
Payers’ Expectations for Biosimilars Reflect a Conflicted Environment
Hopeful but not enthusiastic. Preparing but not anticipating. Those are the impression one gets when speaking to medical directors and pharmacy directors of health plans, insurers, and pharmacy benefit managers about biosimilars today. Although savings associated with biosimilar use have been limited so far, one recently released survey of these payers revealed expectations that seem … Continue reading Payers’ Expectations for Biosimilars Reflect a Conflicted Environment